Posted by Michael Wonder on 06 Aug 2021
Novavax and European Commission finalise advance purchase agreement for up to 200 million doses of COVID-19 vaccine
4 August 2021 - Agreement for 100 million doses with option for additional 100 million doses through 2023.
Novavax today announced that it has reached an agreement with the European Commission for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
